Immix Biopharma's IMX-110 / Anti-PD-1 Combo Therapy Shows Extended Median Survival In Animal Studies

Immix Biopharma Inc's IMMX IMX-110 + anti-PD-1 produced 63-day median survival in a genetic pancreatic cancer mouse model, in which mice develop their own pancreatic cancer and have an intact immune system.

• Historically, 42-days is the median survival produced by a 4-drug combination: 2 chemotherapies and two immunotherapies in the same genetic pancreatic cancer mouse model.
• "This data highlights why we are excited to collaborate with BeiGene on our planned 2022 Phase 1b/2a combination trial of IMX-110 + BeiGene anti-PD-1 tislelizumab in advanced solid tumors," said Ilya Rachman, CEO of ImmixBio. "We believe this upcoming combination clinical trial will allow us to expand into multiple oncology indications rapidly."
• In 2022, the Company plans to commence combination IMX-110 + BeiGene Ltd BGNE anti-PD-1 tislelizumab Phase 1b/2a clinical trial in advanced solid tumors.
• Related: Immix's Lead Program Shows 50% Response Rate In Resistant Cancer In Animal Study.
• The FDA has approved orphan drug designation for IMX-110 for soft tissue sarcoma. Additionally, the FDA has approved rare pediatric disease designation to IMX-110 for rhabdomyosarcoma.
• Price Action: IMMX shares are down 3.07% at $4.10 during the market session on the last check Tuesday.